Natural Capsules Limited

Natural Capsules Dispatches Postal Ballot Notice to Shareholders via E-mail

Natural Capsules Limited is sending postal ballot notices electronically to shareholders. Shareholders with un-registered emails can access the notice via a provided weblink and are instructed to update their KYC details. This process is in compliance with the Companies Act and SEBI regulations.

Natural Capsules Seeks Shareholder Approval for ₹250 Crore Investment/Loan Limit Enhancement

Natural Capsules Limited is seeking shareholder approval via postal ballot to enhance its investment, loan, and guarantee limits to ₹250 Crore under Section 186 of the Companies Act, 2013. Remote e-voting will be open from February 26 to March 27, 2026. The results are expected within two working days post-voting.

Natural Capsules Ltd. Publishes Unaudited Financial Results for Q3 FY26 in Newspapers

Natural Capsules Limited published its unaudited financial results for the quarter ended December 31, 2025. The company reported a standalone net profit after tax of ₹49.33 crore and consolidated net profit after tax of ₹55.03 crore. These results were approved by the Board on February 13, 2026.

Natural Capsules Presents Investor Deck for Q3FY26 Results

Natural Capsules Limited released its Q3FY26 investor presentation. The company faced operational challenges at its Puducherry unit due to regulatory action, impacting revenue which fell 18% QoQ to ₹37.75 crore. Consolidated PAT was ₹(7.12) crore. US trade tariffs have eased, and the company is exploring partnerships for its API fermentation block.

Natural Capsules Q3 FY26 Results: Revenue Declines 18%, PAT Drops 6833%

Natural Capsules reported Q3 FY26 results with revenue down 18% and PAT down 6833% YoY. Puducherry unit operations were impacted by regulatory issues. API fermentation block scale-up faced challenges. US trade tariffs have eased. For 9MFY26, revenue fell 14% and PAT by 20458%.

Natural Capsules Board Approves Q3 FY26 Results, Allots 45,000 ESOP Shares

Natural Capsules Limited's Board approved Q3 FY26 financial results on February 13, 2026. The company also approved the allotment of 45,000 equity shares under its ESOP plan, increasing paid-up capital to ₹10,38,61,540. A postal ballot for enhancing limits under Section 186 was also approved.

Natural Capsules Board Approves Q3 FY26 Results, Allots 45,000 ESOP Shares

Natural Capsules Limited's Board approved Q3 FY26 results on February 13, 2026. The company also approved the allotment of 45,000 equity shares under its ESOP plan, increasing paid-up capital to ₹10,38,61,540. A postal ballot notice for enhancing limits under Section 186 was also approved.

Natural Capsules Board Approves Q3 FY26 Results, Allots 45,000 ESOP Shares

Natural Capsules Limited approved Q3 FY26 unaudited consolidated and standalone financial results. The company also approved the allotment of 45,000 equity shares under its ESOP 2025 plan. This increased the paid-up share capital to Rs. 10,38,61,540.

Natural Capsules Plant Operations Resumed by Madras High Court Order

The Honorable High Court of Madras has suspended the closure order for Natural Capsules Limited's Pondicherry plant, allowing operations to resume. The closure, due to a customer's expired drug license, had caused an estimated ₹6 Crores decrease in sales.

Natural Capsules Ltd: Certificate Under SEBI Reg. 74(5) for Q3 FY26

Natural Capsules Limited submitted a certificate under SEBI Regulation 74(5) for the quarter ended December 31, 2025. The RTA confirmed processing of dematerialization requests and updating of records.

Natural Capsules Ltd: Material Subsidiary Decides Against Rights Issue Allotment

Natural Biogenex Private Limited, a material subsidiary of Natural Capsules Limited, has decided not to proceed with its Rights Issue allotment due to non-subscription by a major shareholder. The decision was confirmed in a Board meeting on January 03, 2026.

Natural Capsules Plant Closure Ordered by Drug Controller Due to Expired License Material

Natural Capsules Limited's Pondicherry plant ordered for temporary closure by the Department of Drug Controller on December 26, 2025. The closure is due to supplying material to a customer whose drug license had expired. The company is taking corrective actions, and the financial impact is yet to be ascertained.

Natural Capsules Ltd. Closes Trading Window for Q4 FY26 Results

Natural Capsules Limited will close its trading window from January 1, 2026, until 48 hours after the declaration of financial results for the quarter ended December 31, 2025. The date of the board meeting for this declaration will be announced later.

Newspaper Publication: Special Window for Physical Share Transfer Re-lodgement

Natural Capsules Limited announced a special window for re-lodgement of transfer requests for physical shares from July 7, 2025, to January 6, 2026, as per SEBI guidelines.

Natural Capsules Limited Q2 & H1 FY'26 Earnings Conference Call Transcript

Natural Capsules Limited's Q2 & H1 FY'26 earnings call highlights revenue growth to ₹45.80 crore, but faces challenges with EBITDA margins and net loss. API production scale-up encounters technical difficulties.

Natural Capsules Limited Releases Audio Recording of November 17, 2025 Conference Call

Natural Capsules Limited has made the audio recording of its conference call from November 17, 2025, available on its website, fulfilling SEBI regulations.

Natural Capsules Limited Publishes Unaudited Financial Results for Q2 & H1 FY26

Natural Capsules Limited published its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, in Business Line and Sanjevani dailies.

NATCAPSUQ Announces Q2 & H1FY26 Results

Natural Capsules Limited (NATCAPSUQ) declared Q2 & H1FY26 results. Revenue for Q2FY26 was ₹45.80 crore & H1FY26 was ₹91.01 crore. The company faced challenges due to US tariffs and technical issues in API production.

Natural Capsules Limited Releases Q2FY26 Investor Presentation, Reports Profitability Decline Amidst Challenges

Natural Capsules Limited reported Q2FY26 results with revenue growth but significant declines in profitability due to US tariffs on HPMC capsules and API scale-up delays. A new production line is expected by Q3FY26.

Natural Capsules Board Approves Q2 & H1 FY26 Results, Opts Out of Subsidiary's Rights Issue

Natural Capsules approved Q2 & H1 FY26 standalone and consolidated results. Standalone profit surged, but consolidated loss increased significantly due to the API subsidiary's ramp-up. Board opted out of subsidiary's rights issue due to cash flow.

NATCAPSUQ Approves Unaudited Results for Quarter Ended 30 Sep 2025

Natural Capsules Limited approved unaudited financial results for the quarter ended September 30, 2025, during a board meeting on November 13, 2025. The board also decided against subscribing to a rights issue.

Natural Capsules Board Approves Q2 FY26 Results; Decides Against Subsidiary's Rights Issue

Natural Capsules' Board approved Q2 FY26 standalone and consolidated financial results. Standalone profit increased, but consolidated loss widened due to subsidiary's new operations. The company will not subscribe to Natural Biogenex's rights issue.

Natural Capsules to hold Q2 & H1 FY26 Earnings Conference Call on November 17, 2025

Natural Capsules Limited will host a conference call on November 17, 2025, to discuss Q2 and H1 FY26 un-audited financial results and business outlook with investors and analysts.

Natural Capsules launches 'Saksham Niveshak' for shareholder KYC and unclaimed funds

Natural Capsules launched "Saksham Niveshak" campaign from July 28 to Nov 6, 2025, to help shareholders update KYC and claim unpaid dividends/shares, preventing transfer to IEPF.

Natural Capsules submits Regulation 74(5) certificate for Q2 FY26

Natural Capsules Limited submitted the Regulation 74(5) certificate for the quarter ended 30th September 2025, confirming compliance with dematerialisation procedures.

Natural Biogenex approves rights issue of ₹1.11 crore

Natural Capsules Limited announces COO Mr. MVN Kutty's retirement due to superannuation

Natural Capsules Limited launches 'Saksham Niveshak' campaign.

Natural Capsules Reports Strong Q1 FY26 Performance: Swings to Profit with Double Revenue Growth

Voting Results and Scrutinizer’s Report of AGM held on 4 Aug 2025

NATCAPSUQ Announces Q1FY26 Results

Natural Capsules Q1 FY26: Standalone Profit Rises, Consolidated Hit by New API Unit Expenses